EP1326842A1 - Arylpiperazinderivate und deren verwendung als psychopharmaka - Google Patents
Arylpiperazinderivate und deren verwendung als psychopharmakaInfo
- Publication number
- EP1326842A1 EP1326842A1 EP01971882A EP01971882A EP1326842A1 EP 1326842 A1 EP1326842 A1 EP 1326842A1 EP 01971882 A EP01971882 A EP 01971882A EP 01971882 A EP01971882 A EP 01971882A EP 1326842 A1 EP1326842 A1 EP 1326842A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- formula
- compounds
- solvates
- acid
- salts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000004089 psychotropic agent Substances 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 64
- 150000003839 salts Chemical class 0.000 claims description 35
- 239000012453 solvate Substances 0.000 claims description 24
- 239000002253 acid Substances 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 6
- 208000028017 Psychotic disease Diseases 0.000 claims description 5
- 239000000556 agonist Substances 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 4
- 150000007513 acids Chemical class 0.000 claims description 4
- 210000003169 central nervous system Anatomy 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 208000019901 Anxiety disease Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 208000020016 psychiatric disease Diseases 0.000 claims description 3
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 2
- 150000007514 bases Chemical class 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 239000002464 receptor antagonist Substances 0.000 claims description 2
- 229940044551 receptor antagonist Drugs 0.000 claims description 2
- 229930192474 thiophene Natural products 0.000 claims description 2
- 101150049660 DRD2 gene Proteins 0.000 claims 1
- 230000000698 schizophrenic effect Effects 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 42
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 36
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 26
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 14
- 102000005962 receptors Human genes 0.000 description 14
- 108020003175 receptors Proteins 0.000 description 14
- 229960003638 dopamine Drugs 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- 238000007792 addition Methods 0.000 description 11
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 11
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 238000010438 heat treatment Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 229910000027 potassium carbonate Inorganic materials 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- -1 3-cyanophenyl Chemical group 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000001530 fumaric acid Substances 0.000 description 6
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 6
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 6
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 201000000980 schizophrenia Diseases 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 206010008118 cerebral infarction Diseases 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 150000004675 formic acid derivatives Chemical class 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000011321 prophylaxis Methods 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- HAYMWIJSIJKEBS-UHFFFAOYSA-N 1-(4-fluorophenyl)-4-[4-(2-methylquinolin-8-yl)piperazin-1-yl]butan-1-one Chemical compound C12=NC(C)=CC=C2C=CC=C1N(CC1)CCN1CCCC(=O)C1=CC=C(F)C=C1 HAYMWIJSIJKEBS-UHFFFAOYSA-N 0.000 description 3
- 208000031295 Animal disease Diseases 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000003693 atypical antipsychotic agent Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 229940076279 serotonin Drugs 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 239000003760 tallow Substances 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- ZORSXSRUAULINY-UHFFFAOYSA-N 1-(4-fluorophenyl)-4-(4-quinolin-8-ylpiperazin-1-yl)butan-1-one Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCN(C=2C3=NC=CC=C3C=CC=2)CC1 ZORSXSRUAULINY-UHFFFAOYSA-N 0.000 description 2
- AITNMTXHTIIIBB-UHFFFAOYSA-N 1-bromo-4-fluorobenzene Chemical compound FC1=CC=C(Br)C=C1 AITNMTXHTIIIBB-UHFFFAOYSA-N 0.000 description 2
- HXAOUYGZEOZTJO-UHFFFAOYSA-N 4-chloro-1-(4-fluorophenyl)butan-1-one Chemical compound FC1=CC=C(C(=O)CCCCl)C=C1 HXAOUYGZEOZTJO-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- 241000251730 Chondrichthyes Species 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 150000001242 acetic acid derivatives Chemical class 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001270 agonistic effect Effects 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 230000000561 anti-psychotic effect Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 description 2
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WLFNETJSPCGPCW-WLHGVMLRSA-N (e)-but-2-enedioic acid;1-(4-fluorophenyl)-4-(4-quinolin-8-ylpiperazin-1-yl)butan-1-ol Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C=2C3=NC=CC=C3C=CC=2)CCN1CCCC(O)C1=CC=C(F)C=C1 WLFNETJSPCGPCW-WLHGVMLRSA-N 0.000 description 1
- 125000005919 1,2,2-trimethylpropyl group Chemical group 0.000 description 1
- QMDPGDCZIVOKNA-UHFFFAOYSA-N 1-(4-chlorobutyl)-4-fluorobenzene Chemical compound FC1=CC=C(CCCCCl)C=C1 QMDPGDCZIVOKNA-UHFFFAOYSA-N 0.000 description 1
- WBLSHIKDVMETTQ-UHFFFAOYSA-N 1-(4-fluorophenyl)-4-(4-quinolin-8-ylpiperazin-1-yl)butan-1-one;dihydrate;trihydrochloride Chemical compound O.O.Cl.Cl.Cl.C1=CC(F)=CC=C1C(=O)CCCN1CCN(C=2C3=NC=CC=C3C=CC=2)CC1 WBLSHIKDVMETTQ-UHFFFAOYSA-N 0.000 description 1
- GSUCSJOIZOUGJB-UHFFFAOYSA-N 1-(4-fluorophenyl)-4-[4-(1h-indol-4-yl)piperazin-1-yl]butan-1-ol;dihydrochloride Chemical compound Cl.Cl.C1CN(C=2C=3C=CNC=3C=CC=2)CCN1CCCC(O)C1=CC=C(F)C=C1 GSUCSJOIZOUGJB-UHFFFAOYSA-N 0.000 description 1
- SJKRNBWFSFWVHZ-UHFFFAOYSA-N 1-(4-fluorophenyl)-4-[4-(1h-indol-4-yl)piperazin-1-yl]butan-1-one Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCN(C=2C=3C=CNC=3C=CC=2)CC1 SJKRNBWFSFWVHZ-UHFFFAOYSA-N 0.000 description 1
- GPBONUQSVFNDGB-UHFFFAOYSA-N 1-(4-fluorophenyl)-4-[4-(1h-indol-4-yl)piperazin-1-yl]butan-1-one;dihydrochloride Chemical compound Cl.Cl.C1=CC(F)=CC=C1C(=O)CCCN1CCN(C=2C=3C=CNC=3C=CC=2)CC1 GPBONUQSVFNDGB-UHFFFAOYSA-N 0.000 description 1
- 125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006219 1-ethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 description 1
- OXQGTIUCKGYOAA-UHFFFAOYSA-N 2-Ethylbutanoic acid Chemical compound CCC(CC)C(O)=O OXQGTIUCKGYOAA-UHFFFAOYSA-N 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- XPVCVGMLJYSAFN-UHFFFAOYSA-N 2-methyl-8-piperazin-1-ylquinoline Chemical compound C12=NC(C)=CC=C2C=CC=C1N1CCNCC1 XPVCVGMLJYSAFN-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- YZKSXUIOKWQABW-UHFFFAOYSA-N 4-piperazin-1-yl-1h-indole Chemical compound C1CNCCN1C1=CC=CC2=C1C=CN2 YZKSXUIOKWQABW-UHFFFAOYSA-N 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- DCUZDOXGNVJQQL-UHFFFAOYSA-N 8-piperazin-1-ylquinoline Chemical compound C1CNCCN1C1=CC=CC2=CC=CN=C12 DCUZDOXGNVJQQL-UHFFFAOYSA-N 0.000 description 1
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- 206010001540 Akathisia Diseases 0.000 description 1
- 206010001541 Akinesia Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 102000007527 Autoreceptors Human genes 0.000 description 1
- 108010071131 Autoreceptors Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- VQPMFTYCTANHFJ-UHFFFAOYSA-N C(C)(=O)O.C(C)(=O)O.C(C=CC(=O)O)(=O)O Chemical compound C(C)(=O)O.C(C)(=O)O.C(C=CC(=O)O)(=O)O VQPMFTYCTANHFJ-UHFFFAOYSA-N 0.000 description 1
- 208000009132 Catalepsy Diseases 0.000 description 1
- 208000018152 Cerebral disease Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010058359 Hypogonadism Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 206010037180 Psychiatric symptoms Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010047853 Waxy flexibility Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- CJCSPKMFHVPWAR-JTQLQIEISA-N alpha-methyl-L-dopa Chemical compound OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 CJCSPKMFHVPWAR-JTQLQIEISA-N 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000006254 arylation reaction Methods 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 150000003938 benzyl alcohols Chemical class 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
- 229960002495 buspirone Drugs 0.000 description 1
- WCGTWYGMQOCFDE-TYYBGVCCSA-N butan-1-ol;(e)-but-2-enedioic acid Chemical compound CCCCO.OC(=O)\C=C\C(O)=O WCGTWYGMQOCFDE-TYYBGVCCSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
- 229960004170 clozapine Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000003931 cognitive performance Effects 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004802 cyanophenyl group Chemical group 0.000 description 1
- 125000004212 difluorophenyl group Chemical group 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- SEALOBQTUQIVGU-QNIJNHAOSA-N dihydroergocornine Chemical compound C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)C)C(C)C)=C3C2=CNC3=C1 SEALOBQTUQIVGU-QNIJNHAOSA-N 0.000 description 1
- 229960004290 dihydroergocornine Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960003133 ergot alkaloid Drugs 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001207 fluorophenyl group Chemical group 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- YPGCWEMNNLXISK-UHFFFAOYSA-N hydratropic acid Chemical compound OC(=O)C(C)C1=CC=CC=C1 YPGCWEMNNLXISK-UHFFFAOYSA-N 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000002197 limbic effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000001979 organolithium group Chemical group 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229940106205 potassium 20 mg Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- HGEYJZMMUGWEOT-UHFFFAOYSA-N roxindole Chemical compound C12=CC(O)=CC=C2NC=C1CCCCN(CC=1)CCC=1C1=CC=CC=C1 HGEYJZMMUGWEOT-UHFFFAOYSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 230000011273 social behavior Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/40—Nitrogen atoms attached in position 8
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
Definitions
- the invention relates to arylpiperazine derivatives, their preparation and their use as psychotropic drugs.
- arylpiperazine derivatives according to the invention can be represented by the general formula I.
- R 1 and R 2 independently of one another H, alkyl -CC 6 or halogen
- the use of classic D 2 antagonists is severely restricted due to their extrapyramidal side effects, especially with chronic administration.
- the extrapyramidal side effects include, for example, tremor, akinesia, dystonia and akathisia (Cavallaro & Smeraldi, CNS Drugs 4: 278-293, 995).
- There are only a few antipsychotics which produce significantly fewer or no extrapyramidal side effects and which are referred to as "atypical neuroleptics" (Kervin, Brit. J. Psychiatry 1964, 141-148, 1994).
- the prototypical atypical neuroleptic clozapine has extremely low extrapyramidal effects Side effects, but causes other serious complications such as the sometimes fatal agranulocytosis (Alvir et al., New Engl. J. Med. 329: 162-167, 1993).
- 5-HT 1A agonists in animals increase the antipsychotic properties of conventional dopamine D 2 antagonists (Wadenberg & Ahlenios, J. Neural. Transm. 74: 195-198, 1988) and the catalepsy induced by dopamine D 2 antagonists ( Costall et al., Neuropharmacology 14: 859-868, 1975) prevent 5-HT- A ⁇ agonistic properties could be advantageous.
- the effectiveness of buspirone, a drug with 5-HTi A agonistic and dopamine D 2 antagonistic properties has been demonstrated in schizophrenia patients (Goff et al., J. Clin, Psychopharmacol. 11: 193-197, 1991).
- Dopamine D 2 antagonists have been developed which also have an affinity for the 5-HT- A receptor, such as mazapertin (Reiz et al., J. Mid.
- the compounds of the formula I and their salts have very valuable pharmacological properties with good tolerability. They mainly affect the central nervous system. In particular, they have a high affinity for receptors of the 5-HT tA type and / or the dopamine D 2 type.
- Compounds of the formula I are particularly preferably simultaneously agonists of the 5-HT- A receptor and antagonists of the D 2 receptor. Binding to additional 5-HTi D / 2A / 2C receptors is not observed.
- Binding properties of the compounds of the formula I can be determined by known 5-HT- A (serotonin) binding test and dopamine binding test (5-HT- A - (serotonin) binding test: Matzen et al., J. Med. Chem., 43 , 1149-1157, (2000) in particular page 1156 with reference to Eur. J. Pharmacol .: 140, 143-155 (1987); dopamine binding tests: Boettcher et al., J. Med. Chem .: 35, 4020-4026, (1992) with reference to J. Neurochem .: 46, 1058-1067 (1986)).
- the compound of formula I differs from the aforementioned atypical neuroleptics.
- the compounds according to the invention can be used for the treatment of diseases which are connected to the serotonin and dopamine neurotransmitter system and in which high-affinity serotonin receptors (5-HT- A receptors) and / or dopamine D 2 receptors involved.
- the most important indication for the administration of the compound of the general formula I are psychoses of all types, in particular also mental illnesses from the schizophrenia group.
- the compounds can also be used to reduce cognitive impairments, i.e. to improve learning ability and memory.
- the compounds of the general formula ⁇ are also suitable for combating the symptoms of Alzheimer's disease.
- the substances of general formula I according to the invention are suitable for the prophylaxis and control of cerebral infarcts (apoplexia cerebri), such as stroke and cerebral ischemia.
- the substances are used to treat diseases such as pathological anxiety, overexcitation, hyperactivity and impaired attention in children and adolescents, profound developmental disorders and disorders in social behavior with mental retardation, depression, OCD and other senses (OCSD) certain sexual Functional disorders, sleep disorders and disorders in food intake, as well as such psychiatric symptoms in the context of age dementia and dementia of the Alzheimer type, i.e. diseases of the central nervous system in the broadest sense, into question.
- diseases such as pathological anxiety, overexcitation, hyperactivity and impaired attention in children and adolescents, profound developmental disorders and disorders in social behavior with mental retardation, depression, OCD and other senses (OCSD) certain sexual Functional disorders, sleep disorders and disorders in food intake, as well as such psychiatric symptoms in the context of age dementia and dementia of the Alzheimer type, i.e. diseases of the central nervous system in the broadest
- Ar preferably represents a phenyl group which is optionally substituted once, twice, three times, four times or five times by one or more groups of shark, -NO 2 or -CN.
- Ar can also have the meaning of a thiophenyl group which is optionally mono- or disubstituted by one or more of the groups Hai, N0 2 , or -CN.
- Ar means in particular fluorophenyl, difluorophenyl, cyanophenyl or tolyl.
- Ar very particularly preferably has the meaning 3-fluorophenyl, 2,4-difluorophenyl, 3-cyanophenyl or 4-fluorophenyl, in particular 4-fluorophenyl.
- B preferably has the meaning -CO- or -C (Ar) (OH) -, in particular -C (4-fluorophenyl) (OH) -.
- R 1 and R 2 independently of one another are preferably H or -CC 6 alkyl, where 1 to 7 hydrogen atoms are optionally replaced by fluorine.
- R 1 and / or R 2 can be branched or unbranched and is preferably methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, tett-butyl and also pentyl, 1-, 2- or 3-methylbutyl, 1, 1-, 1, 2- or 2,2-dimethylpropyl, 1-ethylpropyl,
- R 1 and / or R 2 particularly preferably denotes methyl, ethyl, isopropyl, n-propyl, n-butyl or ferf-butyl.
- the group preferably has one of the following meanings:
- n is preferably 1, 2 or 3, n being 3 being particularly preferred.
- R 1 , R 2 , A, B and Ar can independently assume one of the meanings mentioned above.
- the compounds of the general formula I are the more preferred the more their substituents have preferred meanings and the more preferred these meanings are.
- Compounds selected from the following group of compounds la to Ih are particularly preferred:
- the formula I comprises both each isolated optical antipode and the corresponding optionally racemic mixtures in any conceivable composition.
- a compound of the general formula I can be converted into the corresponding salt (ie acid addition salt) with an acid.
- Acids which produce compatible (i.e. biocompatible and sufficiently bioavailable) salts are suitable for this reaction. It is therefore possible to use inorganic acids such as sulfuric acid or hydrohalic acids such as hydrochloric acid, bromic acid or phosphoric acids such as orthophosphoric acid, nitric acid, sulfamic acid, aliphatic, alicyclic, araliphatic, aromatic or heterocyclic monobasic or polybasic carboxylic acids, sulfonic acids or sulfuric acid derivatives, acetic acid derivatives, acetic acid derivatives, formic acid derivatives, formic acid derivatives, formic acid derivatives, formic acid derivatives, such as formic acid derivatives, Diethyl acetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, lactic acid, tartaric acid, malic acid, benzoic acid, salicy
- the corresponding free bases of general formula I can be released by treating their salts with strong bases such as sodium hydroxide, potassium hydroxide or sodium or potassium carbonate, provided that there are no other acidic groups in the molecule.
- strong bases such as sodium hydroxide, potassium hydroxide or sodium or potassium carbonate
- acid formation can also be brought about by treatment with strong bases.
- Suitable bases are alkali metal hydroxides, alkaline earth metal hydroxides or organic bases in the form of primary, secondary or tertiary amines.
- Solvates of the compounds of the general formula I are understood to mean additions of chemically “inert” solvent molecules to the compounds of the formula I which are formed on account of their mutual attraction.
- Solvates are, for example, mono- and dihydrates or addition compounds with alcohols such as methanol or ethanol ,
- Another object of the invention is the use of a compound of general formula I or one of its compatible salts or solvates for the manufacture of a medicament which is suitable for the treatment of human or animal diseases, in particular diseases of the central nervous system such as pathological Tension, depression and / or psychoses, to reduce side effects in the treatment of high blood pressure (e.g. with a-methyldopa), to treat endoclinological and / or gynecological diseases, e.g. to treat agromegaly, hypogonadism, secondary amenorrhea, postmenstrual Syndrome and unwanted lactation during puberty and for the prophylaxis and therapy of cerebral diseases (e.g.
- migraines particularly in gereatria, in a manner similar to certain Ergot alkaloids and for the control and prophylaxis of cerebral infarction (apoplexia cerebri) such as stroke and cerebral ischemia.
- pharmaceutical preparations and medicaments which contain a compound of the general formula I are suitable for improving cognitive performance and for treating Alzheimer's disease symptoms.
- Such medicinal products are particularly suitable for the treatment of mental illnesses from the schizophrenia group and for combating psychotic anxiety.
- the term treatment includes prophylaxis and therapy of human or animal diseases.
- the substances of the general formula I are normally administered analogously to known, commercially available pharmaceutical preparations (for example bromocriptine and dihydroergocornine), preferably in doses of between 0.2 and 500 mg, in particular between 0.2 and 15 mg, per dose unit.
- the daily dose unit is between 0.001 and 10 mg per kg body weight.
- Low doses between 0.2 and 1 mg per dose unit, 0.001 to 0.005 mg per kg body weight
- a dose between 10 and 50 mg per dose unit is preferred for other indications.
- the dose to be administered depends on a variety of factors, e.g. the effectiveness of the relevant component, the age, body weight and general condition of the patient.
- the invention also relates to the compounds of the formula I as claimed in claim 1 and their physiologically acceptable salts or solvates as active pharmaceutical ingredients.
- the invention furthermore relates to compounds of the formula I according to Claim 1 and their physiologically acceptable salts or solvates as D 2 receptor antagonists and 5HT 1A agonists.
- the invention also relates to the compounds of the formula I as claimed in claim 1 and their physiologically acceptable salts or solvates for use in combating diseases.
- the invention furthermore relates to a process for the preparation of a pharmaceutical preparation which comprises converting a compound of the general formula I or one of its compatible salts or solvates together with a suitable carrier into a suitable dosage form.
- the compounds of the general formula I can be brought into a suitable dosage form together with at least one carrier or auxiliary, optionally in combination with a further active ingredient.
- Suitable carriers are organic or inorganic substances which are suitable for enteral (e.g. oral) or parenteral or topical administration and which do not react with the substances of the general formula I according to the invention. Examples of such carriers are
- Carbohydrates such as lactose and starch, magnesium stearate, tallow and petroleum jelly. Tablets, coated tablets, capsules, syrups, juices,
- Solutions such as suspensions, emulsions or even implants are used for parenteral administration. Ointments, cream or powder are used for external use.
- the compounds of general formula I can also be lyophilized and the resulting ones
- Lyophilisates are processed into injectable preparations.
- the invention further relates to medicaments which contain at least one compound of the general formula I or one of its tolerable salts or solvates and, if appropriate, further ingredients such as Carriers, excipients, etc. These preparations can be used as medicaments for the treatment of human or animal diseases.
- the abovementioned medicaments can be sterilized and processed together with auxiliaries such as lubricants, preservatives, stabilizers and / or moistening agents, emulsifiers, osmotically active substances, buffers, dyes or taste improvers to give other pharmaceutical preparations.
- auxiliaries such as lubricants, preservatives, stabilizers and / or moistening agents, emulsifiers, osmotically active substances, buffers, dyes or taste improvers to give other pharmaceutical preparations.
- the invention further relates to a process for the preparation of compounds of the formula I and their salts and solvates, characterized in that (a) a compound of the formula II
- Leaving group, in particular Cl, tosylate or Br means and optionally, if B is -CO-, the group B is hydrogenated, alkylated or arylated and, if appropriate, a basic or acidic compound of the formula I by treatment with an acid or base in one of them Salts or
- Organolithium reagents for use a complex hydride is preferably used for the hydrogenation
- the compounds of the formula I and also the starting materials for their preparation are otherwise prepared by methods known per se, as described in the literature (for example in the standard works such as Houben-Weyl, methods of organic chemistry, Georg-Thieme-Verlag, Stuttgart) are described, namely under reaction conditions which are known and suitable for the reactions mentioned. Use can also be made of variants which are known per se and are not mentioned here in detail.
- the starting materials can also be formed in situ, so that they are not isolated from the reaction mixture, but instead are immediately reacted further to give the compounds of the formula I.
- arylpiperazine derivatives of the formula are preferably prepared according to the following scheme:
- the molecular weight (M + H + ) is determined with the help of electron spray ionization mass spectroscopy.
- the mass spectroscopic data come from HPLC / MS runs (HPLC coupled with an electrospray ionization mass spectrometer).
- the numerical values are not the molecular weights of the unchanged compounds, but rather the molecular weights of the protonated compounds (hereinafter: [M + H] + ).
- the method is described in the following references: M. Yamashita, JB Fenn, J. Phys. Chem. 88, 1984, 4451-4459; CK Meng et al., Zeitschrift für Physik D 10, 1988, 361-368; JB Fenn et al., Science 246, 1989, 64-71.
- a solution of 100 g of a compound of the general formula I and 5 g of dinathum hydrogenphosphate are adjusted to pH 6.5 in 3 l of double-distilled water with 2 N hydrochloric acid, sterile filtered and filled into injection ampoules, and lyrphilized. Sterile conditions were observed. Each injection ampoule contains 5 mg of the active component of the general formula I.
- a mixture of 20 g of a compound of general formula I is mixed with 100 g of soy lecithin and 1400 g of cocoa butter with heating and poured into wells. Each suppository contains 20 mg of the active component.
- a solution containing 1 g of a compound of the general formula I, 9.38 g of NaH 2 PO 4 x 2 H 2 0, 28.48 g of Na 2 HP0 4 x 12 H 2 0 and 0.1 g of benzalkonium chloride is mixed with 940 ml of twice-distilled water.
- the solution is adjusted to pH 6.8 and made up to one liter with double-distilled water and sterilized by radiation. This solution can be used in the form of eye drops.
- a mixture of 100 g of a compound of general formula I, 1 kg of lactose, 600 g of microcrystalline cellulose, 600 g of corn starch, 100 g of polyvinylpyrrolidone, 80 g of tallow and 10 g of magnesium stearate are mixed and pressed into tablets in the usual way, so that one tablet Contains 100 mg of the active component.
- Tablets are produced as in Example 7 and then coated in a known manner with sucrose, corn starch, tallow, tragacanth and dyes.
- Hard gelatin capsules are filled with a compound of general formula I in a known manner so that each capsule contains 5 mg of the active component.
- inhalation spray 14 g of a compound of general formula I are dissolved in 10 l of isotonic saline.
- the solution is filled into commercially available spray containers that have a pump mechanism.
- the solution can be sprayed into the mouth or nose.
- One spray (approximately 0.1 ml) corresponds to a dose of 0.14 mg of a compound of general formula I.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10043659 | 2000-09-05 | ||
DE10043659A DE10043659A1 (de) | 2000-09-05 | 2000-09-05 | Arylpiperazinderivate |
PCT/EP2001/009108 WO2002020491A1 (de) | 2000-09-05 | 2001-08-07 | Arylpiperazinderivate und deren verwendung als psychopharmaka |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1326842A1 true EP1326842A1 (de) | 2003-07-16 |
Family
ID=7655009
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01971882A Withdrawn EP1326842A1 (de) | 2000-09-05 | 2001-08-07 | Arylpiperazinderivate und deren verwendung als psychopharmaka |
Country Status (15)
Country | Link |
---|---|
US (1) | US20040014972A1 (zh) |
EP (1) | EP1326842A1 (zh) |
KR (1) | KR20030024913A (zh) |
CN (1) | CN1452614A (zh) |
AU (1) | AU2001291744A1 (zh) |
BR (1) | BR0113581A (zh) |
CA (1) | CA2421219A1 (zh) |
CZ (1) | CZ2003809A3 (zh) |
DE (1) | DE10043659A1 (zh) |
MX (1) | MXPA03001826A (zh) |
NO (1) | NO20030998D0 (zh) |
PL (1) | PL360289A1 (zh) |
SK (1) | SK3612003A3 (zh) |
WO (1) | WO2002020491A1 (zh) |
ZA (1) | ZA200302636B (zh) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE424825T1 (de) | 2001-07-20 | 2009-03-15 | Psychogenics Inc | Behandlung von hyperaktivitätsstörungen und aufmerksamkeitsdefiziten |
WO2004082570A2 (en) * | 2003-03-17 | 2004-09-30 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with dopamine receptor d2 (drd2) |
WO2004113333A1 (ja) * | 2003-06-23 | 2004-12-29 | Dainippon Sumitomo Pharma Co., Ltd. | 老人性痴呆症治療剤 |
ES2250000B1 (es) * | 2004-09-29 | 2007-06-01 | Medichem, S.A. | Procedimiento para la preparacion de ziprasidona. |
ES2250001B1 (es) * | 2004-09-29 | 2007-06-01 | Medichem, S.A. | Proceso para la purificacion de ziprasidona. |
KR100660142B1 (ko) * | 2005-01-24 | 2006-12-20 | 이명섭 | 건식 모래 생산 방법 및 그 시스템 |
TWI320783B (en) | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
TW200800959A (en) | 2005-06-10 | 2008-01-01 | Wyeth Corp | Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor |
TW200808730A (en) * | 2006-06-09 | 2008-02-16 | Wyeth Corp | Process for synthesizing piperazine-piperidine compounds |
TW200831096A (en) * | 2006-11-28 | 2008-08-01 | Wyeth Corp | Metabolites of 5-Fluoro-8-{4-[4-(6-methoxyquinolin-8-yl)piperazin-1-yl]piperidin-1-yl} quinoline and methods of preparation and uses thereof |
EP2137162B1 (en) | 2007-03-15 | 2018-08-01 | Novartis AG | Organic compounds and their uses |
US20100041663A1 (en) | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK148392D0 (da) * | 1992-12-09 | 1992-12-09 | Lundbeck & Co As H | Heterocykliske forbindelser |
AU5343498A (en) * | 1997-01-21 | 1998-08-07 | Yoshitomi Pharmaceutical Industries, Ltd. | Thiophene compounds and medicinal use thereof |
ES2128266B1 (es) * | 1997-07-08 | 2000-01-16 | Vita Invest Sa | Compuestos derivados de tiofeno y benzotiofeno y utilizacion y composicion correspondientes. |
EP0900792B1 (en) * | 1997-09-02 | 2003-10-29 | Duphar International Research B.V | Piperazine and piperidine derivatives as 5-HT1A and dopamine D2-receptor (ant)agonists |
-
2000
- 2000-09-05 DE DE10043659A patent/DE10043659A1/de not_active Withdrawn
-
2001
- 2001-08-07 EP EP01971882A patent/EP1326842A1/de not_active Withdrawn
- 2001-08-07 CZ CZ2003809A patent/CZ2003809A3/cs unknown
- 2001-08-07 CA CA002421219A patent/CA2421219A1/en not_active Abandoned
- 2001-08-07 US US10/363,168 patent/US20040014972A1/en not_active Abandoned
- 2001-08-07 CN CN01815154A patent/CN1452614A/zh active Pending
- 2001-08-07 MX MXPA03001826A patent/MXPA03001826A/es unknown
- 2001-08-07 PL PL36028901A patent/PL360289A1/xx unknown
- 2001-08-07 WO PCT/EP2001/009108 patent/WO2002020491A1/de not_active Application Discontinuation
- 2001-08-07 KR KR10-2003-7002743A patent/KR20030024913A/ko not_active Application Discontinuation
- 2001-08-07 BR BR0113581-3A patent/BR0113581A/pt not_active Application Discontinuation
- 2001-08-07 SK SK361-2003A patent/SK3612003A3/sk unknown
- 2001-08-07 AU AU2001291744A patent/AU2001291744A1/en not_active Abandoned
-
2003
- 2003-03-04 NO NO20030998A patent/NO20030998D0/no unknown
- 2003-04-03 ZA ZA200302636A patent/ZA200302636B/en unknown
Non-Patent Citations (1)
Title |
---|
See references of WO0220491A1 * |
Also Published As
Publication number | Publication date |
---|---|
NO20030998L (no) | 2003-03-04 |
DE10043659A1 (de) | 2002-03-14 |
SK3612003A3 (en) | 2003-07-01 |
CN1452614A (zh) | 2003-10-29 |
CA2421219A1 (en) | 2003-03-03 |
BR0113581A (pt) | 2003-07-15 |
WO2002020491A1 (de) | 2002-03-14 |
MXPA03001826A (es) | 2003-06-04 |
ZA200302636B (en) | 2004-09-08 |
CZ2003809A3 (cs) | 2003-06-18 |
AU2001291744A1 (en) | 2002-03-22 |
KR20030024913A (ko) | 2003-03-26 |
US20040014972A1 (en) | 2004-01-22 |
NO20030998D0 (no) | 2003-03-04 |
PL360289A1 (en) | 2004-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0648767B1 (de) | Piperidine und Piperazine, die Wirkungen auf das z.n.s. Zeigen | |
DE69817584T2 (de) | 2-aminopyridin enthaltende kondensierte zyklische systeme als nos hemme | |
EP0683166B1 (de) | 3-Indolylpiperidine | |
DE10315572A1 (de) | Substituierte Pyrazole | |
EP0736525B1 (de) | Benzonitrile als 5-HT Agonisten und Antagonisten | |
EP1068202B1 (de) | 1-(3 -heteroarylpropyl- oder -prop -2-enyl) -4-benzylpiperidine als nmda-rezeptor-antagonisten | |
EP0998474A1 (de) | Piperazin-derivate | |
EP0722942A1 (de) | Indolpiperidin-Derivate | |
EP0529462A1 (de) | Benzodioxanderivate | |
EP1326842A1 (de) | Arylpiperazinderivate und deren verwendung als psychopharmaka | |
EP1611094B1 (de) | Pyrazolverbindungen | |
DE2950135A1 (de) | Basischer aether, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung | |
EP0407844B1 (de) | Indolderivate | |
EP1292592B1 (de) | Heterocyclische aminoalkylpyridinderivate als psychopharmaka | |
EP0007399A1 (de) | Indolalkylamine, diese enthaltende pharmazeutische Zubereitungen und Verfahren zu ihrer Herstellung | |
DE10041574A1 (de) | Chromenonderivate | |
DE2724478C2 (de) | 5,11-Dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-on-derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
EP0993458B1 (de) | 3-benzylpiperidine | |
DE60311000T2 (de) | Indolderivate und deren verwendung als 5-ht liganden | |
DE3000923A1 (de) | Neue n-alkoxy-dithienylpiperidine | |
DE3300477A1 (de) | Neue heterocyclische verbindungen, ihre herstellung und verwendung | |
DE2609245A1 (de) | Chromanderivate, verfahren zur ihrer herstellung und sie enthaltende arzneimittel | |
DE2139082A1 (de) | Substituierte pyrimidine, verfahren zu deren herstellung und sie enthaltende arzneimittel | |
DE2412521A1 (de) | Tricyclische verbindungen | |
EP1718634A1 (de) | Piperidinderivate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20030113 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20040302 |